Icocef 1000mg/500mg Injection is a combination antibiotic formulation containing Ceftriaxone 1000mg and Sulbactam 500mg, indicated for the treatment of a wide range of bacterial infections. Ceftriaxone, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, while Sulbactam, a beta-lactamase inhibitor, enhances the efficacy of Ceftriaxone by preventing enzymatic degradation of the antibiotic. This synergistic combination is effective against both gram-positive and gram-negative pathogens, including beta-lactamase producing strains. Icocef Injection is commonly employed in the management of respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, bone and joint infections, and septicemia. The formulation is administered via intravenous or intramuscular injection, ensuring rapid systemic distribution and achieving therapeutic concentrations in various tissues and body fluids. Dosage and duration of therapy should be individualized based on the severity and type of infection, patient’s renal and hepatic function, and clinical response. Adverse effects are generally mild and may include local injection site reactions, gastrointestinal disturbances, and hypersensitivity reactions. Caution is advised in patients with known allergy to cephalosporins or penicillins. Icocef 1000mg/500mg Injection should be used under strict medical supervision to optimize therapeutic outcomes and minimize resistance development.